Machine learning tools can sift through genetic profiles to predict which patients with obesity will best respond to glucagon-like peptide-1 agonists such as liraglutide (Saxenda/Victoza, Novo Nordisk) or semaglutide (Ozempic/Wegovy, Novo Nordisk), according to a presentation by Mayo Clinic researchers at DDW 2024, in Washington, D.C.
Mayo researchers previously had found that patients with obesity and the “hungry gut” phenotype—meaning they felt hungry